Cannabinoids Show Anti-Cancer Potential in Lab Studies, but Results Remain Contradictory
A critical review found growing evidence that various cannabinoids can kill cancer cells in laboratory and animal studies across multiple cancer types, but contradictory results and uncertain mechanisms limit conclusions.
Quick Facts
What This Study Found
The review analyzed the anticancer evidence for endocannabinoids, phytocannabinoids, and synthetic cannabinoids across multiple cancer types including glioma, breast, prostate, liver, and lung cancer. Both in vitro (cell line) and in vivo (animal) studies showed cannabinoids could inhibit tumor growth through multiple mechanisms.
Key pathways included the ERK signaling pathway and ceramide/lipid signaling. An emerging area was the interplay between autophagy (cellular self-digestion) and apoptosis (programmed cell death) in cannabinoid-induced cancer cell killing. However, results remained contradictory, with some studies showing cannabinoids promoting rather than inhibiting tumor growth under certain conditions.
Key Numbers
Studies covered: glioma, breast, prostate, endothelial, liver, lung cancer. Key pathways: ERK signaling, ceramide signaling. Types of cannabinoids: endo-, phyto-, synthetic. Both pro- and anti-tumor effects documented depending on conditions.
How They Did This
Critical narrative review of preclinical cannabinoid anticancer research. Covered endo-, phyto-, and synthetic cannabinoids across multiple cancer types. Analyzed mechanisms of action including cell signaling pathways, autophagy, and apoptosis.
Why This Research Matters
Cancer patients increasingly use cannabis alongside conventional treatment. Understanding whether cannabinoids genuinely have anticancer properties, and under what conditions they might help versus harm, is critical for informed decision-making and future drug development.
The Bigger Picture
The contradictory nature of the evidence highlights a fundamental challenge: cannabinoid effects on cancer cells are highly dependent on the specific compound, dose, duration, and cancer type. This complexity means blanket statements about cannabis "curing cancer" are not supported, but also means the therapeutic potential has not been dismissed.
What This Study Doesn't Tell Us
Most evidence was preclinical (cell lines and animal models). In vitro results often do not translate to in vivo efficacy. Contradictory findings across studies remained unresolved. The doses used in laboratory studies may not be achievable in the human body. Very few human clinical studies existed at the time.
Questions This Raises
- ?Under what conditions do cannabinoids promote versus inhibit tumor growth?
- ?Can cannabinoid anticancer effects be harnessed without contradictory pro-tumor effects?
- ?Would cannabinoids work as adjuncts to conventional cancer treatments?
Trust & Context
- Key Stat:
- Both pro- and anti-tumor cannabinoid effects documented depending on conditions
- Evidence Grade:
- Review of preclinical evidence; preliminary and contradictory across studies.
- Study Age:
- Published in 2013. Cannabinoid anticancer research has continued, with a small number of clinical trials beginning.
- Original Title:
- Critical appraisal of the potential use of cannabinoids in cancer management.
- Published In:
- Cancer management and research, 5, 301-13 (2013)
- Authors:
- Cridge, Belinda J, Rosengren, Rhonda J(3)
- Database ID:
- RTHC-00668
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis cure cancer?
The evidence does not support this claim. While numerous laboratory studies show cannabinoids can kill cancer cells under specific conditions, results are contradictory (some conditions show tumor promotion), and almost all evidence comes from cell lines and animal models. The gap between killing cancer cells in a dish and treating cancer in humans is enormous.
Should cancer patients use cannabis?
Many cancer patients use cannabis for symptom management (pain, nausea, appetite). Whether cannabinoids have direct anticancer effects in humans remains unproven. The review emphasized that the contradictory preclinical evidence means cannabis should not replace conventional cancer treatment. Patients should discuss cannabis use with their oncology team.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00668APA
Cridge, Belinda J; Rosengren, Rhonda J. (2013). Critical appraisal of the potential use of cannabinoids in cancer management.. Cancer management and research, 5, 301-13. https://doi.org/10.2147/CMAR.S36105
MLA
Cridge, Belinda J, et al. "Critical appraisal of the potential use of cannabinoids in cancer management.." Cancer management and research, 2013. https://doi.org/10.2147/CMAR.S36105
RethinkTHC
RethinkTHC Research Database. "Critical appraisal of the potential use of cannabinoids in c..." RTHC-00668. Retrieved from https://rethinkthc.com/research/cridge-2013-critical-appraisal-of-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.